In a strategic development set to reshape cross-border healthcare trade between South Asia and Eurasia, the Ministry of Health of the Republic of Uzbekistan has aligned with Nutrify Today and Pharma Eurasia to formalize a structured Indo–CIS pharmaceutical and nutraceutical corridor—positioning Uzbekistan as the region’s premier gateway to the Commonwealth of Independent States (CIS) and the wider Eurasian market.
The trilateral initiative integrates policy facilitation, global industry leadership, and a dedicated commercial exhibition platform—creating a scalable and compliance-driven trade architecture for Indian and global manufacturers seeking structured access into high-growth Eurasian markets.
Also Read: Havas Moonfolks Bolsters Growth Ambitions With Erwin Airlangga
For Indian pharmaceutical and nutraceutical exporters, this corridor represents one of the most structured and policy-backed market-entry opportunities available today.
Through this collaboration, we are institutionalising a transparent, technology-enabled trade ecosystem that creates lasting value for all stakeholders”, states Abdulla Azizov, First Deputy Minister of Health & Chairman, Pharmaceutical Industry Development Agency, Republic of Uzbekistan
The Dual-City Architecture: Mumbai + Tashkent
The corridor operates on a synchronized dual-market model:
-
Mumbai (Sumflex & C-Suite Summit) — Global leadership, investment dialogue, and strategic policy convergence, convening CEOs, regulators, investors, and policy leaders from across the pharmaceutical and nutraceutical value chain.
-
Tashkent (Pharma Eurasia 2026) — Trade execution, regulatory collaboration, and CIS market integration, where corridor discussions transition into tangible trade agreements, partnerships, and regulatory pathways.
This structure connects diplomacy, compliance intelligence, and commercial access across two of the world’s most strategically positioned cities for the health industry.
“With Sumflex anchoring global leadership in Mumbai and Pharma Eurasia providing the structured commercial platform in Tashkent, this initiative transforms vision into executable trade architecture”, says Khasim, MTI Executive Director, Nutrify Today.
Pharma Eurasia 2026: The Commercial Execution Platform
The commercial activation of this corridor will take place at Pharma Eurasia 2026, scheduled for 20–22 May 2026 in Tashkent, Uzbekistan. The platform convenes:
-
Pharmaceutical and nutraceutical manufacturers.
-
Ingredient and excipient suppliers.
-
Contract manufacturers and CDMOs.
-
Regulatory authorities and compliance solution providers.
-
Distributors and trade buyers across CIS and Eurasia.
Also Read: Viet Nam Teams Up With US Firms to Attract International Capital
Under the new alignment, Pharma Eurasia becomes the annual institutional marketplace for the Indo–CIS health trade corridor—providing direct buyer access, government-backed engagement, and structured market-entry facilitation.
Our objective is a long-term, policy-aligned ecosystem where innovation, compliance, and cross-border trade converge in a sustainable and scalable manner”, says M. Harikrishnan, Vice President, Tricornio Technologies & Project Director, Pharma Eurasia
Structured Indo–CIS Corridor: Key Focus Areas
-
Regulatory harmonisation and structured bilateral policy dialogue.
-
Supply chain digitisation and documentation standardization.
-
Bilateral investment facilitation and joint venture frameworks.
-
Clinical research and R&D collaboration.
-
Institutional trade matchmaking and market commercialisation enablement.
Nutrify Today will deploy AI-driven regulatory intelligence and compliance infrastructure to support transparent and scalable cross-border nutraceutical trade.
Also Read: Lee Urges Caution Over Reform Measures to Minimize Side Effects
Our engagement with Nutrify Today and Pharma Eurasia embeds transparency and digital tools into a more institutionalised trade and collaboration architecture, while actively welcoming joint-venture cooperation in manufacturing, technology transfer, and regional expansion”, adds Kamila Mirzaeva, Chief International Relations Specialist, Ministry of Health, Republic of Uzbekistan.